Pieris Pharmaceuticals Probability of Future Stock Price Finishing Under 9.62
| PIRSDelisted Stock | USD 13.60 1.41 9.39% |
Pieris |
Pieris Pharmaceuticals Target Price Odds to finish below 9.62
The tendency of Pieris Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 9.62 or more in 90 days |
| 13.60 | 90 days | 9.62 | near 1 |
Based on a normal probability distribution, the odds of Pieris Pharmaceuticals to drop to $ 9.62 or more in 90 days from now is near 1 (This Pieris Pharmaceuticals probability density function shows the probability of Pieris Stock to fall within a particular range of prices over 90 days) . Probability of Pieris Pharmaceuticals price to stay between $ 9.62 and its current price of $13.6 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.05 indicating Pieris Pharmaceuticals market returns are related to returns on the market. As the market goes up or down, Pieris Pharmaceuticals is expected to follow. Additionally Pieris Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Pieris Pharmaceuticals Price Density |
| Price |
Predictive Modules for Pieris Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pieris Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pieris Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pieris Pharmaceuticals is not an exception. The market had few large corrections towards the Pieris Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pieris Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pieris Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.33 | |
β | Beta against Dow Jones | 1.05 | |
σ | Overall volatility | 0.56 | |
Ir | Information ratio | -0.12 |
Pieris Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pieris Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pieris Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pieris Pharmaceuticals is now traded under the symbol PVLA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Pieris Pharmaceuticals generated a negative expected return over the last 90 days | |
| Pieris Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M). | |
| Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
| Latest headline from globenewswire.com: Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of 78.9 Million |
Pieris Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pieris Stock often depends not only on the future outlook of the current and potential Pieris Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pieris Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 26.4 M |
Pieris Pharmaceuticals Technical Analysis
Pieris Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Pieris Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Pieris Pharmaceuticals. In general, you should focus on analyzing Pieris Stock price patterns and their correlations with different microeconomic environments and drivers.
Pieris Pharmaceuticals Predictive Forecast Models
Pieris Pharmaceuticals' time-series forecasting models is one of many Pieris Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Pieris Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Pieris Pharmaceuticals
Checking the ongoing alerts about Pieris Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Pieris Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Pieris Pharmaceuticals is now traded under the symbol PVLA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Pieris Pharmaceuticals generated a negative expected return over the last 90 days | |
| Pieris Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M). | |
| Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
| Latest headline from globenewswire.com: Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of 78.9 Million |
Check out Pieris Pharmaceuticals Backtesting, Pieris Pharmaceuticals Valuation, Pieris Pharmaceuticals Correlation, Pieris Pharmaceuticals Hype Analysis, Pieris Pharmaceuticals Volatility, Pieris Pharmaceuticals History as well as Pieris Pharmaceuticals Performance. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Pieris Stock
If you are still planning to invest in Pieris Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pieris Pharmaceuticals' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Global Correlations Find global opportunities by holding instruments from different markets |